{"analyses":[{"ciLowerLimit":"0.67","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.18","estimateComment":"Hazard ratio \\<1 favours olaparib.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4167","paramType":"Hazard Ratio (HR)","paramValue":"0.89","statisticalComment":"Stratified by received prior chemotherapy for metastatic breast cancer (yes/no) and receptor status.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.2","upperLimit":"21.6","value":"19.3"},{"groupId":"OG001","lowerLimit":"13.9","upperLimit":"21.9","value":"17.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"205"},{"groupId":"OG001","value":"97"}],"units":"Participants"}],"description":"Time from randomisation until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Olaparib 300 mg bd tablets","id":"OG000","title":"Olaparib 300 mg bd"},{"description":"Physician's choice of chemotherapy; capecitabine, vinorelbine, or eribulin","id":"OG001","title":"Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS) consisting of all randomised patients","reportingStatus":"POSTED","timeFrame":"Survival status reviewed every 3 weeks until treatment discontinued, then every 8 weeks until Sep 2017 (final OS DCO), then every 3 months. Assessed up to a maximum of 64 months.","title":"Overall Survival (OS) at Extended OS","type":"SECONDARY","unitOfMeasure":"Months"}